The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model

Human Reproduction

Volumn 26, Issue 9, 2011, Pages 2344-2352

  Schwager, Kathrin ^a   Bootz, Frank ^a   Imesch, Patrick ^b   Kaspar, Manuela ^a   Trachsel, Eveline ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

angiogenesis; Endometriosis; extra domain A of fibronectin; interleukin 10; targeting

Indexed keywords

ANTIBODY CONJUGATE; F8 INTERLEUKIN 10; F8 INTERLEUKIN 2; FIBRONECTIN; HYBRID PROTEIN; SODIUM CHLORIDE; TENASCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENDOMETRIOSIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PROTEIN DOMAIN;

MUS;

EID: 80051947187     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/der195     Document Type: Article

References (61)

1. Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, Hilger CS, Cyr JE, Dinkelborg LM. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005;11:7053s-7063s. (Pubitemid 41428704)
2. Birchler M, Neri G, Tarli L, Halin C, Viti F, Neri D. Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J Immunol Methods 1999a;231:239-248. (Pubitemid 30394737)
3. Birchler M, Viti F, Zardi L, Spiess B, Neri D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol 1999b;17:984-988. (Pubitemid 29474854)
4. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75-85.
5. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003;102:4384-4392. (Pubitemid 37494099)
6. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006;12:3200-3208. (Pubitemid 43837370)
7. Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989;108:1139-1148. (Pubitemid 19083757)
8. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002;99:1659-1665. (Pubitemid 34533039)
9. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003;200:488-499. (Pubitemid 36818249)
10. D'Antonio M, Martelli F, Peano S, Papoian R, Borrelli F. Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol 2000;48:81-98.
11. D'Hooghe TM, Nugent NP, Cuneo S, Chai DC, Deer F, Debrock S, Kyama CM, Mihalyi A, Mwenda JM. Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo-and drug-controlled study. Biol Reprod 2006;74:131-136. (Pubitemid 43068800)
12. Derman AY, Sperling D, Merav A, Jain VR, Levin M, Jana S, Haramati LB. Endometrioma presenting as a cavitary lung mass with intense 18F-FDG uptake on PET-CT. J Thorac Imaging 2007;22:172-175. (Pubitemid 46868290)
13. Dietrich T, Atrott K, Stawowy P, Menssen H, Willuda J, Menrad A, Fleck E, Graf K. Targeted immunocytokine therapy with interleukin-2 reduces plaque formation in aortic lesions from ApoE-deficient mice(abstr). Eur Heart J 2007;28(Suppl):746-747.
14. Fedele L, Somigliana E, Frontino G, Benaglia L, Vigano P. New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs 2008;17:1187-1202.
15. Ferrero S, Gillott DJ, Remorgida V, Anserini P, Ragni N, Grudzinskas JG. GnRH analogue remarkably down-regulates inflammatory proteins in peritoneal fluid proteome of women with endometriosis. J Reprod Med 2009;54:223-231.
16. Folli S, Westermann P, Braichotte D, Pelegrin A, Wagnieres G, van den Bergh H, Mach JP. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res 1994;54:2643-2649. (Pubitemid 24173752)
17. Frey K, Schliemann C, Schwager K, Giavazzi R, Johannsen M, Neri D. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. J Urol 2010; 184:2540-2548.
18. Gafner V, Trachsel E, Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 2006;119:2205-2212. (Pubitemid 44423682)
19. Gillies SD, Lan Y, Wesolowski JS, Qian X, Reisfeld RA, Holden S, Super M, Lo KM. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J Immunol 1998; 160:6195-6203. (Pubitemid 28298086)
20. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-1799. (Pubitemid 39488065)
21. Gutowski M, Carcenac M, Pourquier D, Larroque C, Saint-Aubert B, Rouanet P, Pelegrin A. Intraoperative immunophotodetection for radical resection of cancers: evaluation in an experimental model. Clin Cancer Res 2001;7:1142-1148. (Pubitemid 32708663)
22. Hadfield R, Mardon H, Barlow D, Kennedy S. Delay in the diagnosis of endometriosis: a survey of women from the USA and the UK. Hum Reprod 1996;11:878-880. (Pubitemid 26142192)
23. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002;20:264-269. (Pubitemid 34205419)
24. Huang TH, Chintalacharuvu KR, Morrison SL. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J Immunol 2007;179:6881-6888.
25. Huhn RD, Radwanski E, O'Connell SM, Sturgill MG, Clarke L, Cody RP, Affrime MB, Cutler DL. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996;87:699-705. (Pubitemid 26031078)
26. Husby GK, Haugen RS, Moen MH. Diagnostic delay in women with pain and endometriosis. Acta Obstet Gynecol Scand 2003;82:649-653. (Pubitemid 36735140)
27. Jeffry L, Kerrou K, Camatte S, Metzger U, Lelievre L, Talbot JN, Lecuru F. Endometriosis with FDG uptake on PET. Eur J Obstet Gynecol Reprod Biol 2004;117:236-239. (Pubitemid 39487336)
28. Kaspar M, Trachsel E, Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 2007;67:4940-4948. (Pubitemid 46910202)
29. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, Ishimaru T, Masuzaki H. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010;25:642-653.
30. King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 2004;22:4463-4473. (Pubitemid 41185112)
31. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007;13:331-342. (Pubitemid 47062827)
32. Marlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, Giovannoni L, Neri D. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 2008;14:6515-6524.
33. Matter CM, Schuler PK, Alessi P, Meier P, Ricci R, Zhang D, Halin C, Castellani P, Zardi L, Hofer CK et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res 2004;95:1225-1233. (Pubitemid 39648214)
34. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996;11:220-223. (Pubitemid 26047702)
35. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5:436-446. (Pubitemid 40791486)
36. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 1997;15:1271-1275. (Pubitemid 27465138)
37. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-716. (Pubitemid 32128637)
38. Nisolle M, Casanas-Roux F, Anaf V, Mine JM, Donnez J. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 1993;59:681-684. (Pubitemid 23086336)
39. Ntziachristos V, Yodh AG, Schnall M, Chance B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci USA 2000;97:2767-2772. (Pubitemid 30159246)
40. Pedretti M, Rancic Z, Soltermann A, Herzog BA, Schliemann C, Lachat M, Neri D, Kaufmann PA. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. Atherosclerosis 2010a;208:382-389.
41. Pedretti M, Verpelli C, Marlind J, Bertani G, Sala C, Neri D, Bello L. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer 2010b;103:827-836.
42. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-21776. (Pubitemid 28405353)
43. Rice VM. Conventional medical therapies for endometriosis. Ann NY Acad Sci 2002;955:343-352; discussion 389-393, 396-406. (Pubitemid 34271092)
44. Rosenblum IY, Johnson RC, Schmahai TJ. Preclinical safety evaluation of recombinant human interleukin-10. Regul Toxicol Pharmacol 2002;35:56-71. (Pubitemid 34174541)
45. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003;2:123-131. (Pubitemid 37361644)
46. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 1927;14:422-469.
47. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009;113:2265-2274.
48. Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, Klapper W, Menssen HD, Neri D. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009;113:2275-2283.
49. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5:147-159.
50. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, Trachsel E. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009;11:R142.
51. Shimizu Y, Mita S, Takeuchi T, Notsu T, Mizuguchi K, Kyo S. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids 2011;76:60-67.
52. Somigliana E, Vigano P, Rossi G, Carinelli S, Vignali M, Panina-Bordignon P. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a Murine model of endometriosis. Hum Reprod 1999; 14:2944-2950.
53. Sommavilla R, Lovato V, Villa A, Sgier D, Neri D. Design and construction of a naive mouse antibody phage display library. J Immunol Methods 2010;353:31-43.
54. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann NY Acad Sci 2002;955:89-100; discussion 118, 396-406. (Pubitemid 34271066)
55. Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW, Dinkelborg LM, Leemans CR, Neri D, van Dongen GA. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 2009;36:1235-1244.
56. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007a;9:R9.
57. Trachsel E, Kaspar M, Bootz F, Detmar M, Neri D. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo. J Invest Dermatol 2007b;127:881-886. (Pubitemid 46434663)
58. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000;243:243-255.
59. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rosli C, Borsi L, Neri D. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008; 122:2405-2413. (Pubitemid 351590471)
60. Wan S, Parrish JA, Anderson RR, Madden M. Transmittance of nonionizing radiation in human tissues. Photochem Photobiol 1981; 34:679-681.
61. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987;6:2337-2342.